Form 4: Black Diamond Therapeutics Director Granted Stock Options Valued at $2.43 Per Share

Black Diamond Therapeutics Director Prakash Raman was granted 30,550 stock options with an exercise price of $2.43, vesting over approximately one year.

Summary

• Prakash Raman, a Director at Black Diamond Therapeutics, Inc. (BDTX), was granted 30,550 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $2.43.
• The options are for 30,550 shares of Common Stock.
• The options are set to expire on June 11, 2035.
• The shares subject to this option will vest and become exercisable in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, contingent on Mr. Raman's continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event and not indicative of significant operational or financial changes.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages the director's continued service and commitment to the company.

Future Outlook

The granted stock options are subject to a future vesting schedule, which will occur upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, provided the reporting person continues their service.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically the grant of stock options to a director, which is a common form of equity compensation in the biotechnology and pharmaceutical industries to attract and retain talent and align management incentives with shareholder value.

Related Party Transactions

• The grant of stock options to Prakash Raman, a Director of Black Diamond Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised in the future, but it also aims to align the director's interests with shareholder value creation.
• Director (Prakash Raman): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, subject to the Director's continued service.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Prakash Raman